Insider Selling: Recro Pharma Inc (REPH) CEO Sells 144,806 Shares of Stock

Recro Pharma Inc (NASDAQ:REPH) CEO Geraldine Henwood sold 144,806 shares of Recro Pharma stock in a transaction on Monday, May 13th. The shares were sold at an average price of $8.89, for a total value of $1,287,325.34. Following the transaction, the chief executive officer now owns 342,947 shares in the company, valued at approximately $3,048,798.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

NASDAQ REPH traded up $0.06 on Thursday, reaching $8.93. The stock had a trading volume of 146,876 shares, compared to its average volume of 366,503. The company has a debt-to-equity ratio of 4.04, a current ratio of 3.56 and a quick ratio of 2.08. Recro Pharma Inc has a 1 year low of $4.78 and a 1 year high of $13.05. The company has a market capitalization of $201.17 million, a P/E ratio of -3.59 and a beta of -0.13.

Recro Pharma (NASDAQ:REPH) last issued its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.69. Recro Pharma had a negative return on equity of 654.93% and a negative net margin of 83.56%. The firm had revenue of $25.07 million for the quarter, compared to the consensus estimate of $20.51 million. On average, equities analysts anticipate that Recro Pharma Inc will post -1.94 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of REPH. Renaissance Technologies LLC grew its stake in Recro Pharma by 26.0% in the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock valued at $3,416,000 after purchasing an additional 99,200 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Recro Pharma by 5.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 32,313 shares of the specialty pharmaceutical company’s stock worth $229,000 after buying an additional 1,683 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Recro Pharma by 47.8% in the fourth quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 7,679 shares during the last quarter. Essex Investment Management Co. LLC lifted its position in shares of Recro Pharma by 1.9% in the fourth quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock worth $1,830,000 after buying an additional 4,833 shares during the last quarter. Finally, Monarch Partners Asset Management LLC lifted its position in shares of Recro Pharma by 57.4% in the fourth quarter. Monarch Partners Asset Management LLC now owns 55,857 shares of the specialty pharmaceutical company’s stock worth $397,000 after buying an additional 20,367 shares during the last quarter. Hedge funds and other institutional investors own 56.12% of the company’s stock.

A number of research analysts have recently weighed in on REPH shares. Zacks Investment Research downgraded Recro Pharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 23rd. Janney Montgomery Scott restated a “buy” rating and issued a $13.00 target price on shares of Recro Pharma in a research note on Thursday, January 31st. ValuEngine upgraded Recro Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Oppenheimer restated an “outperform” rating and issued a $9.00 target price (down previously from $19.00) on shares of Recro Pharma in a research note on Monday, March 25th. Finally, Roth Capital restated a “neutral” rating and issued a $7.50 target price (down previously from $15.00) on shares of Recro Pharma in a research note on Monday, March 25th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.95.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Recro Pharma Inc (REPH) CEO Sells 144,806 Shares of Stock” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.thestockobserver.com/2019/05/16/insider-selling-recro-pharma-inc-reph-ceo-sells-144806-shares-of-stock.html.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Story: Price-Sales Ratio

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.